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1.1 Use of Vasopressor
Shock, which normally means a lack of blood flow to a specific area of the body,
results in the oxygen and nutrients not being able to be delivered to the tissues and
thus is a life-threatening situation. Shock comes in a variety of forms: septic shock,
which occurs as a consequence of the inflammatory response to infection, can lead
to respiratory or heart failure. Cardiogenic shock, which in contrast is mostly often
triggered by a heart attack, causes a decrease in the cardiac output and thus leads
to hypoperfusion and hypotension. Hypotension is usually defined by a drop in
systolic blood pressure (SBP) to < 90 mmHg or by at least a 40-mmHg decrease
from baseline. The inadequate perfusion to critical organs (heart, liver and kidneys)
will lead to significant mortality reported to be around 40% to 60% [1]. Septic shock
is also reported to be account for 18% to 50% of ICU mortality [2]. Once septic shock
is formed, immediate and aggressive medical attention is needed. Early effective fluid
resuscitation is crucial to stabilize the resulting tissue hypoperfusion. To achieve
adequate fluid resuscitation, the Surviving Sepsis Guidelines advise at least 30 ml/kg
of crystalloids be infused for most patients in septic shock and fluid should be
aggressively infused for as long as the patient continues to improve hemodynamically
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[2]. Despite fluid resuscitation, vasopressors should be promptly begun in patients in
persistent septic shock. There are a variety of available vasopressors for the clinicians
to use (see Table. 1.1), however, making recommendations on the use of a specific
vasopressor is made difficult by the limited number of controlled experiments and
the fact that these agents are usually used in combination [3]. No study to date has
demonstrated a significant benefit on survival rate of one vasopressor on another [4],
therefore the choice of vasopressor is pretty much empiric. Yet the Surviving Sepsis
Campaign recommends norepinephrine (NE) or dopamine as the first-line agent on
patients presenting septic shock followed by epinephrine to those who respond poorly
to norepinephrine or dopamine [5].
Table 1.1: Vasopressor drug name, clinical indication for therapeutic use, standard
dose range and receptor binding [6].
Receptor Binding
Drug Clinical Indication Dose Range (IV) α1 β1 β2
Dopamine Shock (cardiogenic, vasodilatory) 2.0-20 mcg/kg/min +++ ++++ ++
Dobutamine Low CO (myocardial dysfunction) 2.0-20 mcg/kg/min + +++++ +++
Norepinephrine Shock (vasodilatory, cardiogenic) 0.01-3.0 mcg/kg/min +++++ +++ ++
Epinephrine Shock (vasodilatory, cardiogenic) 0.01-0.1 mcg/kg/min +++++ ++++ +++
Isoproterenol Bradyarrhythmias 2-10 mcg/kg/min 0 +++++ +++++
Phenylephrine Hypotension 0.4-9.1 mcg/kg/min +++++ 0 0
α1 indicates α-1 receptor; β1, β-1 receptor; β2, β-2 receptor; 0, zero significant receptor affinity; + through
+++++, minimal to maximal relative receptor affinity; mcg refers to µg.
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1.2 Vasopressor Dose-Response Modeling
Vasopressors take effect on the cardiovascular endpoints (e.g. heart rate, car-
diac output, mean arterial pressure, systemic vascular resistance) through stimulus
of different receptors. Activation of α1-adrenergic receptors on arterial vascular
smooth muscle cells results in smooth muscle contraction and an increase in sys-
temic vascular resistance (SVR), while β1-adrenergic receptor stimulation results in
enhanced myocardial contractility and stimulation on β2-adrenergic receptor results
in vasodilation [6]. The actual underlying mechanism of vasopressors is by all means
much more complicated than this and thus make it extremely difficult to accurately
describe and model this entire process. However, in the real hospital settings, clini-
cians rarely dig this deep into the exact mechanism of a specific drug. Instead, they
tend to use a simplified model to help them determine how much drug should be
infused to a patient’s body. For example, they may determine using their experience
that a certain dose level of the drug is needed to alter the endpoints to achieve a
desired set point. Such a simplified model is called a drug effect model, which de-
scribes the relationship between the infusion dose and the change in the endpoints.
The drug effect model is typically consisted of two parts, the pharmacokinetics (PK)
part and the pharmacodynamics (PD) part. The pharmacokinetics (PK) part of the
model describes how the infused drug is distributed in the patient’s body while the
pharmacodynamics (PD) part relates the effect site dose to the endpoints.
The most popular PK model is the compartmental model [7,8], which can fur-
ther be divided into smaller categories depending on how many compartments are
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used in the model. The compartmental model divide the human body into several
portions (e.g., tissues, organs, blood) and assign different rates to each compart-
ment to model the absorption and eliminations of drugs. The drug concentration
is assumed to be homogeneous in each compartment and the transmission of drug
between one compartment to another is purely driven by the difference in the con-
centration. The output of the PK model is the plasma concentration Cp. The
PD model in general consists of a first order system (which transforms the plasma
concentration Cp to effect site concentration Ce) and a model that describes the
concentration-effect relationship. This model is usually chosen to be the Emax
model, which utilizes a empirical nonlinear Hill curve to relate the effect site con-
centration by either IV infusion or oral absorption to the corresponding change in
the endpoint.
1.3 Closed-Loop Control
In a surgery, it is usually desirable (sometimes necessary) for the clinicians to
control a set of physiologic indexes (e.g., heart rate, mean arterial pressure, cardiac
output) and hold them within a specific range. Take anesthesia as an example,
closed-loop control of medication infusion has been an active field of research for
a few decades in critical care medicine, with a large number of work reported on
closed-loop control of anesthesia, analgesia, and neuromuscular blockade [9–12]. Tra-
ditionally, the clinicians manually control the drug administration which is based
on their experience, established rules and the measured/predicted patient response.
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In this process, the expert opinion and knowledge is very important because human
body is a sophisticated system and thus suffers from a large intervariability and
intravariability. Besides, manual administration is also prone to human error and
the heavy work load restricts the ability of clinicians to perform other high-level
tasks.
A computer program, on the other hand, can be used to assist the drug ad-
ministration using the prior computation of the dose profile. This is implemented
by a Target-Controlled Infusion (TCI) system [13, 14]. However, TCI is only a
open-loop system rather than a closed-loop system. Since TCI uses pharmacoki-
netics/pharmacodynamics (PKPD) models to predict the patient response and in
real clinical settings real-time plasma/blood drug concentration is extremely diffi-
cult, if not impossible, to obtain. TCI actually estimates the drug concentration
rather than obtains it through measurement, and thus the performance hinges heav-
ily on the accurateness of the patient model. Yet, a variety of factors can alter the
patient’s physiological condition, e.g., surgical stimulation and hypnotic-opioid syn-
ergy. Thus, in the end, TCI still requires human interventions to function properly.
Hence, a more advanced automatic infusion system should have the ability to
adapt itself to different patient conditions. This can be achieved by introducing
a closed-loop control scheme to the system. The advantages of using closed-loop
infusion system over manual administration have been confirmed by many literatures
[15–17], which include smaller steady-state error, improved hemodynamic stability,
shorter recovery time and optimized drug use. To achieve accurate feedback, the
process itself should be defined and representative measures of the system state
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should also be available. Again using controlled anesthesia as an example, clinicians
typically choose compartmental models to describe the drug distribution and indexes
like BIS [18] or WAVCNS [19] as a measure of degree of hypnosis (DoH). These
endpoints have definitive bounds with upper bound being the nominal value and
zero being the lowest possible value. The boundedness of the range of response with
its explicit limits facilitated the use of classical dose-response models, e.g., the Emax
model [20], in designing closed-loop controllers for infusion of these medications (see,
e.g., [18, 21–28]).
In contrast to the above, medications such as vasopressors and inotropes ex-
hibit excitatory dose-dependent effects. A unique challenge associated with closed-
loop control of such medications is that the upper limit of medication-induced ex-
citatory response (a parameter that must be specified to characterize the Emax
model) is unknown. In fact, it is extremely difficult, if not impossible, to determine
the upper limit of response in a patient in real clinical settings due to patient safety
and ethical considerations. Despite this prominent challenge, there has not been
rigorous research effort to establish model-based closed-loop control techniques for
infusion of these medications.
1.4 Thesis Goal and Outline
In an attempt to address this challenge, we present in this thesis a semi-
adaptive closed-loop control approach to infusion of medications that exhibit ex-
citatory dose-dependent effects. We will present a new dose-response model by
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extending a classical dose-response model, used for medications with depressive ef-
fects, by a nonlinear transformation, and extend a semi-adaptive control approach
developed based on a prior work, applicable to depressive dose-response relationship,
to the new dose-response model. Two key advantages of the proposed model are
that it can capture dose-response relationship from baseline to a target set point,
and that it enables linear parameterization, thereby facilitating the control design
task. We will examine the efficacy of the proposed approach using an example of
heart rate (HR) response to a vasoactive medication norepinephrine (NE).
The thesis is organized as follows. In Chapter 2, we will present several po-
tential candidates to replace the traditional Emax model and discuss a little about
their respective structures. In Chapter 3, we will apply these candidate models to
a dataset from an animal experiment, perform system identification and sensitivity
analysis and eventually pick out the best candidate model. In Chapter 4, we will
apply a previously developed semi-adaptive control scheme to the new model and
evaluate its performance through in-silico simulation. The thesis concludes with
Chapter 5 summarizing conclusions and outlining future work.
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Chapter 2: Excitatory Dose-Response Modeling
2.1 Overview
In this chapter, we will first briefly introduce existing models that describe
the drug distribution process and dose-response relationship. Then we will point
out the issue with the existing models and present how we develop the new models
based on them. After that, we will briefly compare the new models with existing
ones and identify their pros and cons.
2.2 Existing Models
2.2.1 Pharmacokinetics/Pharmacodynamics Models
To investigate the effect of NE on different endpoints (heart rate, mean arte-
rial pressure, total peripheral resistance, etc.), a pharmaceutical model is needed to
describe the process of the drug being absorbed by the patient and producing de-
sired effects at the effect site. Traditionally, a pharmacokinetics/pharmacodynamics
(PKPD) model is used to describe such process. The pharmacokinetics (PK) part
of the model provides the concentration-time profile in the patient body fluid (nor-
mally plasma or whole blood) with respect to the administered dose via intravenous
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(IV) infusion or oral absorption. Compartmental pharmacokinetics models are
widely used for this purpose [7]. The most simple compartmental model is the
one-compartment model depicted in Fig. 2.1.
Figure 2.1: One-Compartment model. ka=absorption rate constant, k=elimination
rate constant. [29]
In this model, the drug is assumed to achieve instantaneous distribution through-
out the body and that the drug equilibrates instantaneously between tissues [29].
More complex multi-compartmental models have also been developed to account for
sophisticated dynamics for some drugs. A two-compartmental model, which resolves
the body into a central compartment and a peripheral compartment as shown in
Fig. 2.2.
In the two-compartment model, it is assumed that the drug distributes be-
tween central and peripheral compartment and that the drug does not achieve in-
stantaneous equilibrium between two compartments [29]. A three-compartment
model, which further divides the peripheral compartment into fast-response and
slow-response compartments is also available and frequently used.
On the other hand, the pharmacodynamics (PD) model first transforms the
plasma concentration Cp from the PK model to effect site concentration Ce through
a first-order transfer function and then relates Ce to the observed endpoint effects.
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Figure 2.2: Two-Compartment model. k12, k21 and k are first-order rate constants:
k12=rate of transfer from central to peripheral compartment; k21=rate of transfer
from peripheral to central compartment; k=rate of elimination from central com-
partment [29].
There exists various kinds of PD model, among which are (sigmoid) Emax model,
(sigmoid) Imax model, logarithmic model quadratic model, etc. The most frequently
used PD model is the sigmoid Emax model, which utilizes nonlinear Hill equation to
describe nonlinear concentration-effect relationships [7]. It has the general form:






where the effect E is a function of E0, the baseline value of the endpoint, Emax,
the maximum effect, C, the concentration of the drug, EC50, the concentration of
drug that produces half of the maximal effect and λ, the Hill coefficient, which
determines the shape of the nonlinear curve.
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2.2.2 Direct Dynamic Dose-Response Models
Despite of the traditional PKPDmodel, a direct dynamic dose-response (DDDR)
model is proposed by Hahn et al. [30], whose structure is shown in Fig. 2.3. Com-
pared with PKPD model, the DDDR model directly links the infusion dose to the
endpoint effect, i.e., the true infusion rate Ip is first transformed into hypothetical
dose at the site of action (Ie) and then it is related to the desired endpoints via
Emax model.
Figure 2.3: Traditional PKPD versus direct dynamic dose-response model. [30]
Note that the Emax model used in the PKPD model and in the DDDR model
exhibit a slight difference, i.e., the Emax model in the PKPD model relates the effect
site concentration to the clinical effect, whereas the Emax model in the DDDRmodel
relates the effect site dose rate to the clinical effect. Therefore, EC50 in the PKPD
model, which represents the concentration of drug at the effect site that produces
50% clinical effect is replaced by I50, which represents the effect site dose rate that
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produces 50% clinical effect. Also note that the transfer function G(s) in the DDDR
model has an unity gain, allowing effect site dose Ie to reach infusion dose Ip in the
steady state.






2.2.3 The New Model
The new model proposed by us in this thesis originates from a prior work
by Jin et al. [31], where closed-loop control of anesthesia via propofol infusion is
the subject of study. DDDR model along with the Emax model were utilized in
that work to regulate the respiratory rate (RR) and satisfactory performance was
achieved in the simulation. The endpoint (RR) in that work has definitive bounds,
with its nominal value as an upper bound and zero (0) as a physical lower bound.
However, there is no clear physical upper bound as of heart rate, nor it is easy to
determine a physiological upper bound above which the patient may die from heart
failure due to patient safety concerns and ethical reasons. To migrate the success
in the propofol case to that in the norepinephrine case, we resolve this issue by
assuming that the upper limit is unbounded (i.e., ∞, and this assumption will be
justified later in Chapter 3.4). Specifically speaking, we want to find a map that
transforms the upward-going endpoint response w.r.t effect site dose (Ie) to the
downward-going endpoint response as in the propofol case. Then this is equivalent
to finding a function that transforms the delta change of endpoints (∆HR in this
case) ranging from a finite number to infinity to within a finite range (i.e., from zero
12
to the baseline value) as shown in Fig. 2.4. One possible family of functions is the
so called logistic functions which have a domain ranging from −∞ to ∞ but can
only take a finite range of values.
Figure 2.4: Original norepinephrine response and transformed response.
The two logistic functions considered in this report are inverse tangent function




























Rewriting the above models we have


















Here the delta change (∆HR in this case) is normalized by its baseline value
so that its magnitude is consistent when applying the map to different endpoints.
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However, it should be noted that I50 in these two models does not have the same
meaning as in the first two models. In fact, it is no longer the dose level at which
half of the maximum effect is achieved. To compensate for this, we need to multiply
a constant coefficient to the equation. We further see that by multiplying another
coefficient σ to the equation, these models can be adapted to describe endpoint
behavior of different increase amplitudes. Now the equations become





















The variable I50 in the first two models have become Iσ in these two mod-
els which, depending on the value of σ, represents the dose level at which σ% of
the maximum effect is achieved. The significance of σ will be discussed briefly in
Chapter 2.3 and in detail in Chapter 3.4.
2.3 Model Comparison and Discussion
It should be noted that although traditional PKPD model in theory offers
more accurate description of drug kinematics/dynamics than the DDDR model, it
requires plasma/blood NE concentration to train the PK model. Since real-time
drug concentration is usually not easily obtained, if not impossible, a population
PKPD model for a specific group is used which suffers from large inter-individual
as well as intra-individual variability [32]. If one insists to fit the endpoint data
without plasma/blood NE concentration, it has to be estimated by the population-
based PK model and then passed to the PD model. But then we might well have
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omitted this step and used DDDR model in the first place. That being said, we
are not to criticize the goodness of the PKPD model compared with the DDDR
model, but the fact that the lack of real-time plasma/blood NE concentration in
the experiment data makes the choice of adopting DDDR model instead of PKPD
model inevitable.
Now that the model that relates infusion dose to effect site dose has been
chosen, here comes the time to determine how to connect the effect site dose to the
endpoint response. Among all three nonlinear models we have introduced in the
previous section, Emax model is inarguably the most popular and widely-used dose-
response model [33]. The Emax model [20] utilizes a nonlinear Hill curve to model
the dose-response relationship. The parameter λ is in general larger than 1, resulting
in a ∆E − dose curve with a slight increase at the beginning, a rapidly ascending
stage in the region near I50 and a convergent phase at the end as shown in Fig. 2.5.
In the traditional Emax model, the maximum increase of the endpoint is specified
by the parameter Emax, which is normally taken to be the maximum theoretically
allowed increase. Hence, this number is usually far greater than the actual increase in
the experiments, which will cause problem when performing system identification.
This is due to the fact that the actual dose given to the test subject is usually
small compared with I50 value, and hence the identified I50 will be out of the range
of the dose given, making it hard to verify its accurateness. One possible way
to remedy this is to redefine Emax to be the maximum endpoint change that is
actually achieved (instead of maximum therapeutically allowed increase) w.r.t the
dose profile. However, this requires that Emax be related to specific dose profile
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which is even hard to achieve and nearly impossible if it is to be implemented by a
controller. To resolve this issue, we assume that the upper limit of the endpoint is
unbounded (i.e., ∞). In fact, it is a reasonable simplifying assumption as long as
medication is infused at therapeutic low-dose rates.
Figure 2.5: The ∆E − dose curve for the Emax model.
The remaining two models, i.e., the Atan model and the Exponential model,
inherit the spirit of the traditional Emax model but with some extra modifications
so that they allow the endpoint to become infinity while the dose goes to infinity.
In real clinical settings, however, the dose is never going to be near infinity. Indeed,
it will rarely exceed the suggested dose level of that specific drug by too much, and
thus we do not need to worry about the behavior at the extremely-high dose region
of these models. Yet for the Atan model, we can observe from its ∆E − dose curve
from Fig. 2.6 that for typical increase magnitude (20%-100% of the baseline) of the
heart rate, it does not exhibit a three-phase behavior as the Emax model either.
Indeed, ∆E for Atan model increases more and more quickly when the dose exceeds
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I50 (since the derivative of the tangent function goes to infinity at π/2), it is also not
an ideal candidate to replace the Emax model either. To be more precise, the Atan
model can only mimic the ∆E − dose behavior of the Emax model up to a certain
point (around I50) after which the ∆E − dose curve for the Emax model becomes
concave while that of the Atan model remains convex.
Figure 2.6: The ∆E − dose curve for the Atan model.
For the Exponential model, since the derivative of the natural log function
approaches zero at the infinity, the ∆E − dose curve as shown in Fig. 2.7 gets
flatter and flatter when dose increases. It can also be observed from the ∆E − dose
curve that Exponential model clearly exhibits a three-phase behavior as the Emax
model. And since by model design the endpoint would go to infinity when dose is
infinitely large instead of converging to a specific value as the Emax model, and
that is where the parameter σ kicks in. By introducing the parameter σ, the model
output is set to reach σ% of the increase from the baseline when effect site dose
Ie reaches corresponding Iσ. In a target-control-infusion (TCI) system, the desired
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endpoint level that is to be reached is always known before hand, and thus σ could
be set properly using this information. Besides by doing so, the Iσ identified by
the controller is guaranteed to be the same as the dose level required to raise the
endpoint by the same σ% from the baseline in the Emax model.
Figure 2.7: The ∆E − dose curve for the Exponential model.
In this chapter, we have introduced two different categories of model that
describes the distribution of the medication inside the subject’s body, namely PKPD
model and DDDR model. We have shown that although the traditional PKPD
model makes more intuitive sense in modeling the kinematics/dynamics of the drug,
the lack of real-time plasma/blood drug concentration somewhat neutralizes this
advantage and make it less attractive than the DDDR model. That is why we
choose to use the DDDR model in the remaining chapters of this thesis. Then we
introduced three models that describes the dose-response relationship of the drug,
namely Emax model, Atan model and Exponential model. Among them, the Emax
model is the most widely used model for the drugs that depress the endpoint [33].
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However, when used to describe excitatory dose-response relationship, we are faced
with the issue that maximum meaningful endpoint increase (Emax) is usually hard
to determine. The remaining two models are proposed to get around this issue.
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Chapter 3: System Identification and Sensitivity Analysis
3.1 Overview
In the previous chapter, we have presented two models (PKPD and DDDR
model) to describe the drug distribution in the subject’s body and three models
(Emax, Atan and Exponential model) to describe the dose-response relationship of
the drug. Due to the lack of real-time plasma/blood NE concentration, the PKPD
model is not going to be considered here. In this chapter, we will validate and analyze
these models by fitting the heart rate (HR) response of 5 piglets whose dataset comes
from an animal experiment under the protocol approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of North Carolina, Chapel Hill.
Each animal received NE at 5-6 distinct infusion rates of approximately 10 min
duration under general anesthesia and mechanical ventilation to elicit a wide range
of HR response. The minimum and maximum infusion rates used ranged between
0.05 mcg/kg/min and 0.5 mcg/kg/min, which resulted in a maximum HR response
of 32-70 bpm, amounting to 22.1-64.8 % change from the baseline HR. All data are
recorded using an 1 kHz sampling rate but is down-sampled to 10 Hz to lower the
computational load. Besides, we also pre-process the HR measurements with an
15-point median filter to remove noise and outliers. The processed HR response of
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these 5 pigs are shown in Fig. 3.1.
Figure 3.1: Heart rate dose-response of 5 pigs.
It should be noted that the HR response of pig 8 is very abnormal compared
with other pigs, i.e., the HR response from 5-35 min decreases even though the dose
level is actually increasing, which does not make sense. For this reason, the HR
response of pig 8 is excluded from further analysis and only the remaining 4 pigs
(namely, pig 6,7,9,10) are used. Besides, the HR response from 59 min to the end
of pig 7 is far slower than the first 59 minutes of the data and is thus also excluded
from the analysis.
3.2 System Identification
In this section we will perform system identification of the three models men-
tioned above by fitting the model to the experimental data associated with each
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animal. More specifically, we will formulate and solve the following optimization





where θ∗ is optimum value of θ minimizing the cost function (3.1), R̃(t)
and R(t, θ) the measured versus model-predicted HR responses, where the model-
predicted HR response was computed via pure (i.e., infinite-step-ahead) prediction.
For the Atan and Exponential model we will examine the accuracy and parameters
of the models identified with different values of σ. We will use the root-mean-
squared error (RMSE) between measured versus model-predicted HR responses as
the measure of accuracy.
3.2.1 Discretization
In the DDDR model, the drug distribution is governed by the following first-
order system
İe(t) = −keIe(t) + keu(t) ≜ F (Ie(t)) (3.2)
where u(t) is the infusion dose level and Ie(t) is the hypothetical effect site
dose level. We discretize (3.2) as follows:
Ie(t)− Ie(t− 1)
h
= −keIe(t) + keu(t) ⇒ Ie(t) =
1
1 + keh
Ie(t− 1) + hu(t) (3.3)
where h = 1/600 min is the sampling interval. The dose-response relationship
for the three models are discretized similarly using the backward difference scheme.
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3.2.2 Emax Model
The Emax model has the following dose-response relationship:
R(t) = R0 +Rm
Iλe (t)




where R0 is the baseline HR, Rm the maximum therapeutically meaningful increase,
R(t) the medication HR response, Ie(t) the effect site dose, I50 the dose required to
reach half the effect of Rm and λ the Hill coefficient.
To investigate if this system is identifiable, the following matrix needs to have























































where L denotes the Lie derivative





· F, LnFH = L1F (Ln−1F H), x = [Ie, ke, Rm, I50, λ] (3.6)
Since the matrix A is extremely tedious, the column rank of the matrix is
computed and verified using Mathematica:
The parameter constraints for different pigs are listed in Table. 3.1. The upper
bound of Rm is set to roughly two times of the maximum increase observed across
all 4 pigs.
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Figure 3.2: Computation of rank of the identifiability matrix for the Emax model.
Pig 6 Pig 7 Pig 9 Pig 10
RMSE [bpm ] 6.176 2.647 1.287 1.731











Pig 6 0.1-5.0 120.0-140.0 0-160.0 0-5.0 0-10.0
Pig 7 0.1-5.0 90.0-110.0 0-160.0 0-5.0 0-10.0
Pig 9 0.1-5.0 125.0-140.0 0-160.0 0-5.0 0-10.0
Pig 10 0.1-5.0 100.0-110.0 0-160.0 0-5.0 0-10.0
Table 3.1: Parameter bounds on 4 pigs with the Emax model.
The fitting result is shown in Fig. 3.3 and Table. 3.2 and the corresponding
optimal parameters are listed in Table. 3.3.
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Pig 6 0.1050 131.5 52.90 0.2015 3.597
Pig 7 0.9387 105.7 160.0 0.4340 1.144
Pig 9 0.5400 129.8 57.19 0.2446 2.282
Pig 10 0.4157 104.3 70.66 0.2317 1.369
Table 3.3: Optimal parameters for the Emax model.
It should be noted that pig 7 never seems to actually achieve steady state, i.e.,
at the end of each dose level, the HR response is still increasing slightly, and thus it
causes the parameter Rm to saturate. This will result in a biased estimate of other
parameters for pig 7, however, we can do nothing about it.
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3.2.3 Atan Model
The Atan model has the following dose-response relationship:










where R0 is the baseline HR, R(t) the medication HR response, Ie(t) the effect site
dose, Iσ the dose required to increase the HR by σ% of its baseline value and λ the
Hill coefficient.
Again, in order for the system to be identifiable, the following matrix needs





































where L denotes the Lie derivative





· F, LnFH = L1F (Ln−1F H), x = [Ie, ke, Iσ, λ] (3.9)
Since the matrix A is extremely tedious, the column rank of the matrix is
computed and verified using Mathematica:
The parameter constraints for different pigs are listed in Table. 3.4. Note that
here we have used the same parameter constraints regardless of the σ value in the
model.
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Pig 6 0.1-5.0 90.0-110.0 0-5.0 0-10.0
Pig 7 0.1-5.0 90.0-110.0 0-5.0 0-10.0
Pig 9 0.1-5.0 125.0-140.0 0-5.0 0-10.0
Pig 10 0.1-5.0 100.0-110.0 0-5.0 0-10.0
Table 3.4: Parameter bounds on 4 pigs with the Atan model.
The fitting result is shown in Fig. 3.5 and Table. 3.5 and the corresponding
optimal parameters are listed in Table. 3.6.
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Figure 3.5: Predicted vs measured HR of the 4 pigs using the Atan model. Predicted
HR using different σ are superimposed and plotted in the same figure.
RMSE [bpm] Pig 6 Pig 7 Pig 9 Pig 10
σ = 20 6.261 2.701 1.366 1.780
σ = 25 6.254 2.700 1.360 1.785
σ = 50 6.246 2.679 1.371 1.771
σ = 75 6.249 2.664 1.385 1.775
σ = 100 6.252 2.657 1.396 1.780










σ = 20 0.1082 130.7 0.2029 2.361
σ = 25 0.1080 130.7 0.2288 2.347
σ = 50 0.1077 130.7 0.3381 2.215
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σ = 75 0.1077 130.7 0.4318 2.123
σ = 100 0.1077 130.6 0.5158 2.067
Pig 7
σ = 20 0.8829 104.2 0.0697 0.9722
σ = 25 0.8812 104.4 0.0944 0.9941
σ = 50 0.8907 104.8 0.2296 1.023
σ = 75 0.8984 104.9 0.3841 1.001
σ = 100 0.9014 104.9 0.5610 0.9747
Pig 9
σ = 20 0.5307 129.4 0.2236 1.901
σ = 25 0.5314 129.4 0.2600 1.872
σ = 50 0.5307 129.3 0.4275 1.750
σ = 75 0.5303 129.3 0.5803 1.684
σ = 100 0.5300 129.3 0.7221 1.646
Pig 10
σ = 20 0.4156 103.9 0.1232 1.217
σ = 25 0.4156 103.9 0.1556 1.210
σ = 50 0.4157 104.0 0.3317 1.146
σ = 75 0.4158 103.9 0.5316 1.100
σ = 100 0.4158 103.9 0.7488 1.071
Table 3.6: Optimal parameters for the Atan model.
It should be noted that we did not optimize σ during the system identification
process. Instead, we set σ = 20/25/50/75/100 and fit the models to the response
29
separately. From Table. 3.5 we see that changing σ in the model merely has an
effect on the fitting. However, changing σ does influence the estimate of Iσ and λ
as expected.
3.2.4 Exponential Model
The Exponential model has the following dose-response relationship:











where R0 is the baseline HR, R(t) the medication HR response, Ie(t) the effect site
dose, Iσ the dose required to increase the HR by σ% of its baseline value and λ the
Hill coefficient.
Again, in order for the system to be identifiable, the following matrix needs





































where L denotes the Lie derivative





· F, LnFH = L1F (Ln−1F H), x = [Ie, ke, Iσ, λ] (3.12)
Since the matrix A is extremely tedious, the column rank of the matrix is
computed and verified using Mathematica:
The parameter constraints for different pigs are listed in Table. 3.7. Note that
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Figure 3.6: Computation of rank of the identifiability matrix for the Exponential
model.










Pig 6 0.1-5.0 90.0-110.0 0-5.0 0-10.0
Pig 7 0.1-5.0 90.0-110.0 0-5.0 0-10.0
Pig 9 0.1-5.0 125.0-140.0 0-5.0 0-10.0
Pig 10 0.1-5.0 100.0-110.0 0-5.0 0-10.0
Table 3.7: Parameter bounds on 4 pigs with the Exponential model.
The fitting result is shown in Fig. 3.7 and Table. 3.8 and the corresponding
optimal parameters are listed in Table. 3.9.
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Figure 3.7: Predicted vs measured HR of the 4 pigs using the Exponential model.
Predicted HR using different σ are superimposed and plotted in the same figure.
RMSE [bpm] Pig 6 Pig 7 Pig 9 Pig 10
σ = 20 6.196 2.837 1.286 1.736
σ = 25 6.205 2.777 1.303 1.733
σ = 50 6.231 2.669 1.356 1.750
σ = 75 6.243 2.648 1.381 1.765
σ = 100 6.249 2.643 1.395 1.774










σ = 20 0.1066 131.1 0.2018 3.019
σ = 25 0.1068 131.0 0.2289 2.768
σ = 50 0.1073 130.7 0.3536 2.291
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σ = 75 0.1075 130.7 0.4610 2.141
σ = 100 0.1077 130.6 0.5559 2.067
Pig 7
σ = 20 1.053 107.1 0.0946 2.072
σ = 25 1.013 106.8 0.1123 1.787
σ = 50 0.9415 105.9 0.2359 1.260
σ = 75 0.9221 105.4 0.4076 1.099
σ = 100 0.9140 105.2 0.6178 1.022
Pig 9
σ = 20 0.5366 129.7 0.2249 2.199
σ = 25 0.5346 129.6 0.2659 2.054
σ = 50 0.5312 129.4 0.4602 1.775
σ = 75 0.5304 129.3 0.6358 1.685
σ = 100 0.5300 129.3 0.7969 1.642
Pig 10
σ = 20 0.4154 104.4 0.1232 1.5663
σ = 25 0.4155 104.3 0.1569 1.437
σ = 50 0.4157 104.0 0.3616 1.189
σ = 75 0.4158 103.9 0.6026 1.110
σ = 100 0.4158 103.9 0.8646 1.072
Table 3.9: Optimal parameters for the Exponential
model.
It should be noted that we did not optimize σ during the system identification
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process. Instead, we set σ = 20/25/50/75/100 and fit the models to the response
separately. From Table. 3.8 we see that changing σ in the model merely has an
effect on the fitting. However, changing σ does influence the estimate of Iσ and λ
as expected.
3.3 Sensitivity Analysis
In this section, we will perform sensitivity analysis using the above-mentioned
three models to determine the relative importance of the parameters in each model.
As we will mention in detail in Chapter 4.2, we specifically want to see that λ has
the least sensitivity so that we can fix λ at its nominal value in the controller set-
tings. The parameter sensitivity function is calculated using the formula in Khalil’s
”Nonlinear Systems” [36].
3.3.1 Emax Model
For the Emax model, the parameter set is θ = [ke, R0, Rm, I50, λ]
T . However,
we are only interested in the sensitivity of ke, I50 and λ. Using eqs. (3.2) and (3.4),




































































, and θ =[
ke, I50, λ
]T
. Considering that limt→∞
∂Ie(t)
∂Iσ






































e−ke(t−τ)[u(τ)− Ie(τ)] dτ . The sensitivity plot is shown in Fig. 3.8.
Figure 3.8: Sensitivity of the parameters using the Emax model.
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3.3.2 Atan Model
For the Atan model, the parameter set is θ = [ke, R0, Iσ, λ]
T . However, we are
only interested in the sensitivity of ke, Iσ and λ. Using eqs. (3.2) and (3.7), the












































































, and θ =[
ke, Iσ, λ
]T
. Considering that limt→∞
∂Ie(t)
∂Iσ
= 0 and limt→∞
∂Ie(t)
∂λ
= 0, (3.15b) re-




































e−ke(t−τ)[u(τ)− Ie(τ)] dτ . The sensitivity plot is shown in Fig. 3.9.
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Figure 3.9: Sensitivity of the parameters using the Atan model.
3.3.3 Exponential Model
For the Exponential model, the parameter set is θ = [ke, R0, Iσ, λ]
T . However,
we are only interested in the sensitivity of ke, Iσ and λ. Using eqs. (3.2) and (3.10),





























































, and θ =[
ke, Iσ, λ
]T
. Considering that limt→∞
∂Ie(t)
∂Iσ
= 0 and limt→∞
∂Ie(t)
∂λ
= 0, (3.18b) re-





























e−ke(t−τ)[u(τ)− Ie(τ)] dτ . The sensitivity plot is shown in Fig. 3.10.
Figure 3.10: Sensitivity of the parameters using the Exponential model.
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3.4 Discussion
3.4.1 More on Exponential Model
As mentioned earlier, we want λ to have the least sensitivity compared with
ke and Iσ/I50 so that we can fix λ at its nominal value in the controller and thus
to enable linear parametrization (see Chapter 4.2). From the results we obtained
above, it can be seen that for the Emax model the magnitude ratio between the
sensitivity of R(t) to ke versus λ and I50 versus λ are given by:∣∣∣∣SR,ke(t)SR,λ(t)
∣∣∣∣ → λIe(ln I50 − ln Ie(t)) ∂Ie(t)∂ke∣∣∣∣SR,Ie(t)SR,λ(t)
∣∣∣∣ → λI50(ln I50 − ln Ie(t)) (3.20)
while for the Atan and Exponential model∣∣∣∣SR,ke(t)SR,λ(t)
∣∣∣∣ → λIe(ln Iσ − ln Ie(t)) ∂Ie(t)∂ke∣∣∣∣SR,Ie(t)SR,λ(t)
∣∣∣∣ → λIσ(ln Iσ − ln Ie(t)) (3.21)
Ideally, these two ratios should be as large as possible, i.e., the models sensi-
tivity to λ must be negligible relative to ke and Iσ/I50 [31]. However for the Emax
model, since we do not know the relative magnitude of Ie(t) and I50 before hand, it
is impossible to reliably guarantee that these ratios are going to be large and thus
making it less legitimate to use population averaged value for λ in the controller
settings. But for Atan and Exponential model, given that both ratios in (3.21)
are infinite if Iσ = Ie(t) (assuming that
∂Ie(t)
∂ke
̸= 0, which is always satisfied during
transients), one way to fulfill the requirements in (3.21) is to set Iσ as the value
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of Ie(t) in the steady state. This can be easily achieved, for example, by setting σ
consistently with the control set point (i.e., if the set point associated with R(t) is
σ∗ % increase from R0, set σ = σ
∗).
At this point with the results from the system identification and sensitiv-
ity analysis, we can compare the pros and cons of the Emax model, Atan model
and Exponential model with more confidence. The Emax model is inarguably the
most popular model [33], but it faces the difficulties that either Emax is hard to
determine for individual subject or that if it is fixed at the therapeutically allowed
maximum value, we run the risk of having the experiment doses almost entirely in
the sub-maximal region and thus endangering the estimate of I50. The Atan and
Exponential model however, get around these issues by allowing the endpoints to go
to infinity (although it never will in the real world) and by setting the σ parameter
in accordance with the desired target point. The introduction of σ also brings along
another advantage, i.e., the sensitivity of λ is the least compared with ke and Iσ
at the steady state. Combined with the fact that the steady state is usually much
longer than the transient state in the actual clinical settings, it makes the choice to
use population averaged λ in the controller more legitimate. Within the Atan and
Exponential model, the dose-response curve for the Atan model approaches a ver-
tical line (i.e., the subject responds more and more violently with increasing dose)
which does not make physiological sense. The Exponential model, in contrast, has
a very similar three-phase dose-response curve as the Emax model. In particular,
since the derivative of the natural log function approaches zero at the end, marginal
dose effect is going to decrease when the dose is very large which resembles the
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Emax model. Despite all the aforementioned advantages, the Exponential model
still have one disadvantage, i.e., since the dose-response curve of the Exponential
model assumes no upper bound whereas the Emax model does have one, the Expo-
nential model can only mimic the behavior up to a certain dose level. However, this
is compensated by the fact that (1) the estimated HR from the Exponential model
is the same as that from the Emax model at the steady state and (2) the transient
tracking error can be alleviated by using larger controller gains.
3.4.2 Accuracy of Parameter Estimation
The results of the system identification analysis (see Table. 3.8) using ex-
perimental data showed that the Exponential model could reproduce experimental
dose-response relationship accurately regardless of the choice of σ (Fig. 3.11; also
see the consistency in the RMSE values against different σ values in Table. 3.10).
In addition, the estimated model parameters were plausible. Specifically, we antici-
pated that Iσ value would be estimated to be proportional to σ due to its definition,
while ke and λ values would be independent of σ. Table. 3.10 clearly shows these
anticipated trends: on the average, the variability in ke and λ with respect to σ was
small, while Iσ exhibited a much larger variability with a proportionally increasing
trend with σ, which is consistent with the notion that Iσ designates the infusion
rate corresponding to σ % increase in response from the baseline.
Fig. 3.12 compares Iσ values obtained directly from experimental data versus
estimated from system identification. We extracted the former from the experimen-
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Figure 3.11: Representative example of intravenous versus model-predicted hypo-
thetical effect site norepinephrine (NE) infusion rates (left), and the resulting mea-
sured versus model-predicted heart rate (HR) responses (right) in an animal.
RMSE [bpm] ke [min
−1] Iσ [mcg/kg/min] λ [·]
σ = 25 1.3-6.2 0.11-1.0 0.11-0.27 1.4-2.8
σ = 50 1.3-6.2 0.11-0.94 0.24-0.46 1.2-2.3
σ = 75 1.4-6.2 0.11-0.92 0.41-0.64 1.1-2.1
σ = 100 1.4-6.2 0.11-0.91 0.56-0.87 1.0-2.1
Table 3.10: Root-mean-squared prediction errors (RMSEs) and the range of model
parameter values associated with all animals with respect to σ.
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tal data by (i) computing the % increase in HR at the end of each step infusion dose
(e.g., 0.05, 0.1, 0.15, and 0.2 mcg/kg/min in Fig. 3.11; % increase was computed as
the average of the last 1 minute associated with each infusion dose), (ii) denoting
the % increase in HR associated with each infusion dose as σ, and (iii) defining
Iσ as the corresponding step infusion dose (e.g., 0.05 mcg/kg/min in Fig. 3.11 was
defined as I6, because it resulted in 6 % increase in HR). Overall, measured and es-
timated Iσ values were consistent in all animals, which supports quantitatively the
validity of the dose-response model derived from the system identification (except
in pig 6, in which the medication distribution dynamics was slow (ke = 0.11min
−1,
corresponding to a 2 % settling time of 35.6 min) and steady state was not reached
within the step infusion duration of 10 min). The other explanation to the defect in
Pig 6 may be that the HR response during 5-15 min is lower than expected for some
unknown reason since the HR during this period is almost lower than HR during
all the other dose levels (as shown in Fig. 3.7) whereas the dose level corresponding
to this period (0.2 mcg/kg/min) is not. If we exclude this portion of the data in
the fitting process, i.e., the fitting error is this portion of the data is not considered
in minimizing the cost function (3.1), the result is shown in Fig. 3.13 and average
fitting error reduces from around 6.2 bpm to around 5.8 bpm. It can be seen that
the Iσ estimates from both sources agree better than before. However, this does not
necessarily means that this explanation is preferred over the previous one. Instead
we simply observe the defect between the measured data and estimated response
and propose reasonable causes that account for the discrepancy, and more rigorous
reasoning should come from further animal experiments.
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Figure 3.12: Comparison of Iσ values obtained directly from experimental data
(circle) versus estimated from system identification (triangle).
Figure 3.13: Comparison of Iσ values obtained directly from experimental data
(circle) versus estimated from system identification (triangle) with a portion of the
data in Pig 6 excluded from system identification process.
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Considering that the traditional Emax model and the Exponential model are
different in terms of the way the steady-state infusion dose parameter is specified,
the ability to estimate Iσ accurately is a meaningful strength of the Exponential
model. The former specifies IEmax50 with respect to the maximum response, whereas
the latter specifies Iσ with respect to the baseline response. Thus, the accuracy
of IEmax50 is subject to compromise in case the maximum response is inadequately
estimated (which is highly probable in real clinical settings now that it is extremely
challenging to estimate the maximum response in the absence of response data
associated with very high infusion dose regimes). In contrast, the accuracy of Iσ is
easier to guarantee because the baseline response is almost always available.
Although the accuracy and parametric plausibility of the Exponential model
were shown to be robust against the choice of σ, it is not clear what is the best choice
of σ to maximize its amenity to control design and system identification. Considering
that parametric accuracy is an important requirement for system identification, it is
desired that the model parameters (especially Iσ which dictates the models steady-
state validity) is accurately estimated. Thus, we want to investigate the parametric
accuracy of the Exponential model with respect to the infusion rate amplitude and
the value of σ. Of particular interest was to gain insights as to how to set the
value of σ when an infusion rate input is given in order to maximize the accuracy of
Iσ. To this end, we constructed a ground truth Emax model (3.22), where R̄0, k̄e,
ĪEmax50 , and λ̄ denote nominal (i.e., average) parameters obtained from the system
identification of the Emax model in all the animals, and R̄m the maximum possible
change in response (specified as twice the maximum change in response across all
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the animals):
İe(t) = −k̄eIe(t) + k̄eu(t), R(t) = R̄0 + R̄m
I λ̄e (t)




Note that ĪEmax50 in (3.22) denotes the steady-state infusion rate to elicit 50%
of maximum response R̄m. Then, we simulate the ground truth Emax model with
a set of infusion rate inputs to generate input-output data pairs, and identify the
Exponential model associated with each input-output data pair. We specifically
employed 3 step infusion rate inputs to simulate the ground truth model, with
the maximum rates corresponding to 25%, 50%, and 75% increases in response
relative to the baseline. In identifying the Exponential model for each input-output
data pair, we used σ = 20, 25, 50, 75, 100. Then, we examined the accuracy of the
identified Iσ values.
Figure 3.14: Estimation error associated with Iσ of model Mσ, σ = 20, 25, 50, 75, 100
when subject to 25 %, 50 %, and 75 % step increase in HR. (a) 25 % HR increase.
(b) 50 % HR increase. (c) 75 % HR increase.
Fig. 3.14 shows that the error associated with Iσ estimated from step response
system identification is minimized when σ is set to the actual steady-state % change
in the systems response. These results suggest that semi-adaptive control may bene-
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fit from setting σ consistently to the specified target set point (i.e., the % difference
between the baseline state and target), by minimizing the unwanted influence of
λ on control efficacy as well as estimation error on Iσ. Note that σ may be reset
recursively, e.g., each time the target set point is varied by the caregiver.
3.4.3 Tuning the Sensitivity
In Chapter 3.4.1, we have proven that the sensitivity of the Exponential model
to λ relative to ke and Iσ can be made small by specifying σ in the model as the
percent change in response induced by the infusion rate inputted to the model. To
verify this, we constructed nominal dose-response models, denoted as Mσ, relating
NE infusion rate to HR associated with different values of σ based on the dose-
response models obtained from system identification (Table. 3.3). We specifically
considered σ = 25, 50, 75, 100. Then, we excited eachMσ using 4 step inputs eliciting
25 %, 50 %, 75 %, and 100 % change in HR, and examined the time evolution of
the parametric sensitivity functions (3.18). In particular, we compared the relative
magnitudes of the parametric sensitivity functions across all the 4 nominal models
for each step infusion rate input to examine if the models sensitivity to λ is the
smallest when σ used in the model is consistent with the input applied to the model.
Fig. 3.15 shows that the sensitivity of the response to λ can be made zero (after
initial transient) by setting the value of σ incorporated in the Exponential model
(3.10) to the actual % change in response.
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Figure 3.15: Time evolution of parametric sensitivity functions associated with mod-
els Mσ, σ = 25, 50, 75, 100. (a) 25 % HR increase. (b) 50 % HR increase. (c) 75 %
HR increase. (d) 100 % HR increase.
For all of the reasons above, we are going to use Exponential model (combing
with the DDDR model) to describe the full dose-response relationship of NE and
implement the model into the controller in the following chapter.
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Chapter 4: Semi-Adaptive Closed-Loop Controller Design
4.1 Overview
Closed-loop control of medication infusion has been an active field of research
for a few decades in critical care medicine, with a large number of work reported
on closed-loop control of anesthesia, analgesia, and neuromuscular blockade [9–12].
These medications commonly exhibit depressive dose-dependent effects, often with
minimum possible response of zero. For example, propofol depresses the degree
of consciousness, which is measured by indices such as BIS ranging between 100
(fully awake) and 0 (fully asleep) [37]. Remifentanil depresses respiratory rate,
also ranging between its nominal value (when not infused) and zero (in case over-
dosed) [38, 39]. The boundedness of the range of response with its explicit upper
(baseline) and lower (zero) limits facilitated the use of classical dose-response models,
e.g., the Emax model [20], in designing closed-loop controllers for infusion of these
medications (see, e.g., [18, 21–28]).
In contrast to the above, medications such as vasopressors and inotropes ex-
hibit excitatory dose-dependent effects. A unique challenge associated with closed-
loop control of such medications is that the upper limit of medication-induced ex-
citatory response (a parameter that must be specified to characterize the Emax
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model) is unknown. In fact, it is extremely difficult, if not impossible, to determine
the upper limit of response in a patient in real clinical settings due to patient safety
and ethical considerations. A conceivable alternative may be to estimate the upper
limit via advanced control techniques, e.g., adaptive control. However, given that
the infusion rate may mostly reside in sub-maximal dose regime (where desired effect
is maximized while dangerous side effects are prevented), the credibility of estimated
upper response limit (and accordingly, other parameters in the model influenced by
the upper response limit) is expected to be low due to the rare incidence of appro-
priate dose-response data in the neighborhood of maximal dose regime. Despite this
prominent challenge, there has not been rigorous research effort to establish model-
based closed-loop control techniques for infusion of these medications. In fact, most
existing work employ empiric model-free techniques such as PID, fuzzy logic, and
rule-based techniques [40–42].
In an attempt to address this challenge, we present a semi-adaptive closed-loop
control approach to infusion of medications that exhibit excitatory dose-dependent
effects. We developed a new dose-response model (the Exponential model, as men-
tioned in the previous chapters) by extending a classical dose-response model (the
Emax model) used for medications with depressive effects by a nonlinear trans-
formation, and extended a semi-adaptive control approach developed in our prior
work [31], applicable to depressive dose-response relationship, to the new dose-
response model. Two key advantages of the proposed model are that it can capture
dose-response relationship from baseline up to target set point, and that it enables
linear parameterization, thereby facilitating the control design task. We will ex-
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amine the efficacy of the proposed approach using an example of heart rate (HR)
response to a vasoactive medication norepinephrine (NE).
4.2 Semi-Adaptive Control Design
Here in this chapter we will use the aforementioned Exponential model in
the controller design. For the sake of convenience, we reformulate the Exponential
model as follows (Fig 4.1)























Figure 4.1: Structure of the Exponential model used to describe excitatory dose-
response relationships.
where u(t) is the intravenous medication infusion rate, Ie(t) the infusion rate
at the (hypothetical) effect site, ke the time constant associated with the distribution
of medication between blood and effect site, x(t) the output of the Emax model with
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cooperativity constant λ, R(t) the medication response, R0 the baseline response
(i.e., in the absence of medication infusion), and kσ a constant specifying the degree
of medication effect. This model consists of a classical Emax model eqs. (4.1a)
and (4.1b) (in which the minimum response is assumed to be zero, i.e., the maximum
dose-dependent effect is equal to R0; see (4.1b)) and a nonlinear transformation






Equation (4.1c) transforms 0 < x(t) ≤ 1 to R0 ≤ R(t) < ∞ in case k < 0 (Fig. 1).
In addition, noting that x(t) = 1/2 and R(t) = R0[1− k ln 3] when Ie(t) = Iσ, Iσ is
defined as the effect site infusion rate associated with σ % increase in response R(t)
from the baseline R0 by specifying kσ = −σ/ ln 3 :
Ie(t) = Iσ → x(t) =
1
2
→ R(t) = R0[1− kσ ln 3] = R0[1 + σ] (4.3)
In our prior work, we developed a semi-adaptive control approach to the infu-
sion of medications with depressive dose-response relationship [31]. The key idea of
the approach was to enable linear parameterization of the Emax model (eqs. (4.1a)
and (4.1b)) by fixing its low-sensitivity parameter λ at a nominal value. To extend
the semi-adaptive control paradigm to the Exponential model (4.1), it is of interest
to examine the parametric sensitivity associated with this model. As we have shown
in Chapter 3.4, λ can be made to be the least sensitivie by setting σ in accordance
with the desired target point. Hence, λ can be safely replaced by its population
averaged value.
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Under the assumption that λ is fixed at a nominal value in (4.1), the Exponen-
tial model (4.1) can be cast into a linearly parameterized model. From eqs. (4.1b)







where λ̄ is the nominal value of λ. Then, the dynamics associated with Ie(t) in
(4.1a) can be expressed in terms of the transformed output variable y(t) as follows:




which can be linearly parameterized with respect to ke and ke/Iσ . Hence, standard
adaptive control techniques, such as model reference adaptive control (MRAC) [43],
can be employed to regulate y(t), and accordingly, R(t). To this end, consider the
following reference model dictating the desired behavior of the closed-loop controlled
medication response:
ẏm(t) = −amym(t) + amr(t) (4.6)
where ym(t) is the desired response, r(t) the bounded reference, and am a positive
constant. The goal of control design is to formulate an adaptive control law to
asymptotically drive y(t) towards ym(t): limt→∞ y(t) = ym(t). Building upon the
MRAC technique, consider the control law given by:
u(t) = âr(t)r(t) + ây(t)y(t)− pe(t) (4.7)
where e(t) = y(t)−ym(t) is the tracking error, âr(t) and ây(t) the adaptive feedback
gains, p the non-adaptive feedback gain. It can be shown that the plant dynamics
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ây(t) = ay = (ke − am) Iσke . Yet, in practice, ar and ay are unknown and must be
estimated from dose-response data. If we define the discrepancy between ar and ay





 âr(t)− am Iσke
ây(t)− (ke − am) Iσke
 (4.8)
The dynamics of the tracking error associated with the control law (4.7) is given by:
































where ϕ(t) = [r(t), y(t)]T . If we emply the following Lyapunov function can-



















and γ1, γ2 > 0 are the adaptive gains, the time derivative of the
































































is bounded. Hence, the plant (4.5)
subject to the control law (4.7) with the adaptive law (4.12) is globally stable, and
the signals e(t), ãr(t), and ãy(t) are bounded. Then, it can be claimed that e(t) is also














= 0, which, together with (4.13), leads to limt→∞ e(t) = 0.
4.3 Semi-Adaptive Control Evaluation
To validate and analyze the efficacy of the semi-adaptive control based on
the proposed new dose-response model, we conducted a set of in-silico testing as
follows. First, we constructed 100 in-silico subjects as plant models in the form of the
Emax model (3.22), by randomizing its parameters within the respective parametric
range obtained from the Emax models identified for all the animals while setting
R̄0 = 118. Second, we simulated the proposed semi-adaptive control law (4.7) and
(4.12) in these plant models. Especially, we simulated the control law with r(t)
corresponding to the set points of 25 %, 50 %, and 75 % increase in HR response
with respect to the baseline (hence a total of 300 in-silico tests) to examine the
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efficacy of the controller across diverse target set points. For each given set point,
we incorporated the corresponding value of σ in control design, i.e., in transforming
R(t) to y(t) via (4.4). We likewise simulated a non-adaptive controller (in which
˙̂ar(t) = ˙̂ay(t) = 0 in (4.12) with âr(t) = am
Īσ
k̄e
and ây(t) = (k̄e − am) Īσk̄e ∀t, where k̄e
and Īσ are nominal values) under the same scenarios to compare semi-adaptive and
non-adaptive controls. Third, we quantified the performance of the controllers in
terms of the speed of response (5 % settling time), root-mean-squared error (RMSE)
during the transient (defined as the first 9.5 min of HR response), and steady-state
error. Fourth, we examined the quality of the parameters estimated by the adaptive
law (4.12) by computing the discrepancy between true versus estimated Iσ in the
steady state in all the subjects associated with all the set points.
To perform realistic in-silico testing, we incorporate the following details.
First, we simulate measurement noise: we use a zero-mean white noise with a stan-
dard deviation (SD) of 1.4 bpm based on the noise characteristics observed from
our experimental data. Second, we simulate zero-order-hold and quantization to
account for finite temporal and spatial resolutions in controller computation: we
use 1 Hz sensing and control update rates as well as 1 bpm HR resolution. Third,
we robustify the control law: we augment the control law with (i) a 15-th order
causal moving average filter to mitigate the adverse influence of measurement noise;
and (ii) a dead zone scheme to prevent the drift of parameter estimates when the
patients HR response is regulated at a target set point.
To produce 100 randomized Emax models, we use the following paramet-
ric envelopes obtained from system identification: 0.11min−1 ≤ ke ≤ 0.94min−1,
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0.20mcg/kg/min ≤ I50 ≤ 0.43mcg/kg/min, and 1.1 ≤ λ ≤ 3.6. To implement






, and p = 2.5. In addition, we set a dead zone width of 2.0 bpm
considering the measurement noise characteristics.
4.3.1 Results and Discussion
Table. 4.1 summarizes the performance of semi-adaptive control relative to
non-adaptive control in terms of transient and steady-state characteristics, while
Fig. 4.3 illustrates representative in-silico testing cases associated with semi-adaptive
versus non-adaptive control. Here, we selected the best and worst cases as follows:
(i) we normalized the transient RMSE and steady-state error in each individual
by their respective mean values; (ii) we computed the aggregated error associated
with each individual as the sum of the normalized transient RMSE and steady-state
error; and (iii) we selected the best and worst cases as the individuals associated
with minimum and maximum aggregated error, respectively. Overall, semi-adaptive
control achieved superior consistency in transient response to its non-adaptive coun-
terpart: (i) its 5% settling time was persistently close to the target value of 10.0
min while non-adaptive control suffered from large variability (up to 76% from the
target in terms of mean value); and (ii) RMSE in reference model tracking during
the transient was > 30% smaller in semi-adaptive than in non-adaptive control.
In addition, semi-adaptive control outperformed non-adaptive control in terms of
steady-state performance as well: the mean and standard deviation of absolute HR
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error in the steady state were > 41.3% and > 17% smaller in semi-adaptive than in
non-adaptive control, despite the dead zone scheme incorporated in the former that
negatively impacted its steady-state tracking performance. The standard deviation
of transient RMSE (both SA and NA cases) and steady-state error (NA) is rougly
proportional to the amount of increase of HR (see Fig. 4.2), which is as expected
due to the random distribution of the parameters of the random subjects. The stan-
dard deviation of steady-state error in SA case is almost constant despite of the σ
value because it is only affected by dead-zone and white noise (since Iσ estimate will
converge to its true value in the end) and thus it is much smaller than that of NA
case. In sum, the results strongly indicate that semi-adaptive control is superior to
its non-adaptive counterpart in achieving uniform response characteristics against











SA 9.35± 1.33 1.05± 0.128 0.810± 0.528
NA 8.51± 1.64 1.50± 0.220 1.38± 0.636
50
SA 10.5± 0.766 1.12± 0.213 0.601± 0.403
NA 13.0± 1.79 2.14± 0.582 2.20± 0.690
75
SA 10.7± 0.566 1.40± 0.281 0.745± 0.533
NA 17.6± 2.24 4.96± 1.59 5.82± 1.79
Table 4.1: Performance of semi-adaptive and non-adaptive controllers associated
with 25%, 50%, and 75% change in set point response with respect to the baseline.
SA: semi-adaptive control. NA: non-adaptive control.
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Figure 4.2: Errorbar plot of the controller performance comparison in Table. 4.1.
Figure 4.3: Representative in-silico testing cases. (a) Semi-adaptive control. (b)
Non-adaptive control.
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Note that, although the influence of λ on the steady-state performance of semi-
adaptive control can be removed by setting σ according to the target set point, its
influence on transient response may still persist. In particular, λ smaller (greater)
than its nominal value tends to elicit fast (slow) transient response through an
increase in the dose-response sensitivity, and Iσ smaller (greater) than its nominal
value, as well as ke greater (smaller) than its nominal value, exert an synergistic
influence on this tendency through a further increase in the dose-response sensitivity
and the speed of medication distribution dynamics.
Fig. 4.4 presents the distribution of Iσ errors associated with the semi-adaptive
control in response to 25%, 50%, and 75% target set points (N=100 each). The
estimates of Iσ were highly accurate regardless of target set point (< 8.6%), which
may not be surprising considering the large sensitivity of the systems response to
Iσ (Fig. 3.15). But more obviously, it is expected to be estimated without any
error in theory, because Iσ is nothing but the infusion rate in the steady state when
σ is set to the % change in response from the baseline. In fact, the small errors
shown in Fig. 4.4 were incurred mostly due to the dead zone scheme, which stopped
adaptation under small set point tracking errors, as well as the measurement noise.
The ability to accurately estimate Iσ is an advantage in that the knowledge of Iσ may
be useful in securing the safety of semi-adaptive control by preventing the infusion
of unacceptably high dose beyond the therapeutic limit of each patient.
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Figure 4.4: Distribution of Iσ errors associated with semi-adaptive control in re-
sponse to 25%, 50%, and 75% target set points.
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Chapter 5: Conclusions and Future Works
In this thesis we have proposed a new dose-response model to describe ex-
citatory dose-dependent effects and presented the application of a semi-adaptive
control approach to this model using norepinephrine (NE) as the drug and heart
rate (HR) as the desired endpoint. An immediate extension to this work would be to
consider a multi-input-multi-output version of the system, i.e., infusion of multiple
vasopressors and simultaneous control of multiple endpoints. Besides, the proposed
semi-adaptive controller along with the new model has not been used and tested in
any in-vivo animal experiments, and thus it remains a question as to how good the
controller would perform in the real experiments despite of the good results obtained
from in-silico computer simulations. Since in the simulation we used Emax model to
generate the hypothetical HR response and the response from a real animal would
undoubtedly be different from that, therefore an in-vivo experiment is needed to
evaluate the efficacy of the proposed controller.
Besides, the DDDR model used in this new model assumes no time-delay,
i.e., the drug arrives at the effect site immediately after the infusion. Although
there is no obvious evidence from the experimental data supporting the existence
of the time-delay in the system, it is still counter-intuitive to believe that the drug
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achieves instantaneous distribution at the effect site. Hence, it might be interesting
to introduce time-delay into the system. By doing so, the stability of the controller
also needs to be reconsidered since time-delay in the feedback process can seriously
deteriorate the performance of the controller.
Additionally, it might also be of interest to investigate the accurateness of
Emax model as the base model. It is shown in the area of anesthesia control that the
parameters of Emax model (EC50 and shape factor λ) are different for induction and
recovery [44], i.e., loss of consciousness and recovery of consciousness might be two
asymmetrical processes. Although there has not been reports with similar evidence
on the vasopressor, it is definitely worth the time and effort to better understand
the underlying mechanism of vasopressors, ideally all the way down to the molecular
level so that models that better describe the process could be invented.
In the controller simulation, the artificial pump delivers whatever infusion rate
that is obtained by the adaptive law. In many of the cases, spikes, i.e., the abrupt
change in the infusion rate, appears during the infusion. In reality, however, the
actual infusion profile would be much smoother than its theoretical counterpart
because the pump itself is subject to its own dynamics. It takes time for the pump
to start or stop the infusion or to transit to a new infusion rate, but the pump
dynamics is not considered in the simulation. Therefore, future work may consider
incorporating the pump dynamics (perhaps as a first-order system) to the entire
model so that the calculated infusion rate can be more realistic.
Besides, it is assumed that baseline value of HR can be accurately obtained
in this work, which is normally the case because it can be obtained by making
63
the patient lie down on the bed doing nothing and then average the measured HR
during the period. However, for those who suffer from severe injuries and are sent
to the hospital for emergent treatment, it is neither ethical to waste precious time
to try to measure the baseline value of various endpoints, nor it is possible to do
this because the endpoints of these patients are already far away from normal values
and are changing rapidly due to the injuries. Thus, the effect of not being able to
have accurate baseline value should also be studied.
Ultimately, since closed-loop control of infusion control is only a part of the
bigger picture, which is to develop a fully automated critical care monitoring system,
it is of great importance to understand how to put different subsystems together
and have them work seamlessly without any conflicts.
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B. Trillat, L. Barvais, and M. Fischler, “Titration of propofol for anesthetic
induction and maintenance guided by the bispectral index: Closed-loop versus
manual controla prospective, randomized, multicenter study,” The Journal of
the American Society of Anesthesiologists, vol. 104, no. 4, pp. 686–695, 2006.
[16] T. De Smet, M. M. Struys, M. M. Neckebroek, K. Van den Hauwe, S. Bonte,
and E. P. Mortier, “The accuracy and clinical feasibility of a new bayesian-
based closed-loop control system for propofol administration using the bispec-
tral index as a controlled variable,” Anesthesia & Analgesia, vol. 107, no. 4,
pp. 1200–1210, 2008.
[17] T. M. Hemmerling, S. Charabati, C. Zaouter, C. Minardi, and P. A. Mathieu,
“A randomized controlled trial demonstrates that a novel closed-loop propofol
system performs better hypnosis control than manual administration,” Can J
Anaesth, vol. 57, no. 8, pp. 725–35, 2010.
66
[18] W. M. Haddad, T. Hayakawa, and J. M. Bailey, “Adaptive control for non-
negative and compartmental dynamical systems with applications to general
anesthesia,” International Journal of Adaptive Control and Signal Processing,
vol. 17, no. 3, pp. 209–235, 2003.
[19] J.-O. Hahn, G. A. Dumont, and J. M. Ansermino, “Robust closed-loop con-
trol of hypnosis with propofol using wav cns index as the controlled variable,”
Biomedical Signal Processing and Control, vol. 7, no. 5, pp. 517–524, 2012.
[20] J. Macdougall, Analysis of Dose–Response Studies—Emax Model. New
York, NY: Springer New York, 2006, pp. 127–145. [Online]. Available:
http://dx.doi.org/10.1007/0-387-33706-7 9
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